REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 219 filers reported holding REATA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.91 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $11,773,525 | -28.3% | 115,472 | -36.0% | 1.88% | -49.7% |
| Q1 2023 | $16,416,879 | +114.8% | 180,564 | -10.3% | 3.72% | +102.0% |
| Q4 2022 | $7,643,588 | +89.4% | 201,200 | +25.3% | 1.84% | +129.6% |
| Q3 2022 | $4,035,000 | -27.4% | 160,564 | -12.2% | 0.80% | -20.7% |
| Q2 2022 | $5,555,000 | -77.4% | 182,805 | -75.7% | 1.01% | -68.7% |
| Q1 2022 | $24,629,000 | +211.3% | 751,805 | +150.6% | 3.24% | +174.6% |
| Q4 2021 | $7,911,000 | -86.5% | 300,000 | -48.4% | 1.18% | -71.3% |
| Q3 2021 | $58,450,000 | +136.1% | 581,000 | +232.2% | 4.12% | +105.6% |
| Q2 2021 | $24,755,000 | +135.3% | 174,900 | +65.8% | 2.00% | +465.3% |
| Q1 2021 | $10,519,000 | -48.9% | 105,500 | -36.7% | 0.35% | -61.0% |
| Q4 2020 | $20,596,000 | +21.2% | 166,600 | -4.5% | 0.91% | -26.2% |
| Q3 2020 | $17,000,000 | -56.6% | 174,500 | -30.4% | 1.23% | -60.5% |
| Q2 2020 | $39,130,000 | +116.9% | 250,800 | +100.6% | 3.11% | +129.5% |
| Q1 2020 | $18,043,000 | – | 125,000 | – | 1.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |